Your browser doesn't support javascript.
loading
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Richardson, Paul G; Durie, Brian G; Rosiñol, Laura; Mateos, Maria-Victoria; Dispenzieri, Angela; Moreau, Philippe; Kumar, Shaji; Raje, Noopur; Munshi, Nikhil; Laubach, Jacob P; O'Gorman, Peter; O'Donnell, Elizabeth; Voorhees, Peter; Facon, Thierry; Bladé, Joan; Lonial, Sagar; Perrot, Aurore; Anderson, Kenneth C.
Afiliación
  • Richardson PG; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Paul_Richardson@dfci.harvard.edu.
  • Durie BG; Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA.
  • Rosiñol L; Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona.
  • Mateos MV; University Hospital of Salamanca, IBSAL, Institute of Cancer Molecular and Cellular Biology, Salamanca.
  • Dispenzieri A; Division of Hematology, Mayo Clinic Cancer Center, Rochester, Minnesota.
  • Moreau P; Hematology Department, University Hospital Hôtel-Dieu, Nantes.
  • Kumar S; Division of Hematology, Mayo Clinic Cancer Center, Rochester, Minnesota.
  • Raje N; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Munshi N; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Laubach JP; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • O'Gorman P; Department of Haematology, Mater Misericordiae University Hospital, University College Dublin, Dublin.
  • O'Donnell E; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Voorhees P; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC.
  • Facon T; University of Lille, Centre Hospitalier Universitaire Lille, Service des Maladies du Sang, Lille.
  • Bladé J; Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona.
  • Lonial S; Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta.
  • Perrot A; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse.
  • Anderson KC; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Haematologica ; 108(11): 2894-2912, 2023 11 01.
Article en En | MEDLINE | ID: mdl-37608773
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans Idioma: En Revista: Haematologica Año: 2023 Tipo del documento: Article País de afiliación: Marruecos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans Idioma: En Revista: Haematologica Año: 2023 Tipo del documento: Article País de afiliación: Marruecos